ERD

Circulating Tumor DNA Genomics Reveal Potential Mechanisms of Resistance to BRAF-Targeted Therapies in Patients with BRA...

Project: TKI resistance

Updated at: 27-04-2024

Show more information

Project acronym TKI resistance

Clinical Relevance of an Amplicon-Based Liquid Biopsy for Detecting ALK and ROS1 Fusion and Resistance Mutations in Pati...

Project: TKI resistance

Updated at: 27-04-2024

Show more information

Project acronym TKI resistance

Acquired Resistance Mutations to ALK Inhibitors Identified by Single Circulating Tumor Cell Sequencing in ALK -Rearrange...

Project: TKI resistance

Updated at: 27-04-2024

Show more information

Project acronym TKI resistance

Diverse resistance mechanisms to the third-generation ALK inhibitor lorlatinib in ALK-rearranged lung cancer

Project: TKI resistance

Updated at: 27-04-2024

Show more information

Project acronym TKI resistance

<p>Profile of entrectinib and its potential in the treatment of ROS1-positive NSCLC: evidence to date</p>

Project: TKI resistance

Updated at: 27-04-2024

Show more information

Project acronym TKI resistance

Facts and new hopes on selective FGFR inhibitors in solid tumors

Project: TKI resistance

Updated at: 27-04-2024

Show more information

Project acronym TKI resistance

Gilteritinib overcomes lorlatinib resistance in ALK-rearranged cancer

Project: TKI resistance

Updated at: 27-04-2024

Show more information

Project acronym TKI resistance

Making the first move in EGFR-driven or ALK-driven NSCLC: first-generation or next-generation TKI?

Project: TKI resistance

Updated at: 27-04-2024

Show more information

Project acronym TKI resistance

Periodic Reporting for period 4 - TKI resistance (Resistance mechanisms to tyrosine kinase inhibitors in solid tumors)

Project: TKI resistance

Updated at: 27-04-2024

Show more information

Project acronym TKI resistance

Sequential ALK Inhibitors Can Select for Lorlatinib-Resistant Compound ALK Mutations in ALK-Positive Lung Cancer

Project: TKI resistance

Updated at: 27-04-2024

Show more information

Project acronym TKI resistance

Single cell DNA-seq depicts clonal evolution of multiple driver alterations in osimertinib resistant patients

Project: TKI resistance

Updated at: 27-04-2024

Show more information

Project acronym TKI resistance

Lorlatinib in ALK- and ROS1-positive NSCLC: the future has a start

Project: TKI resistance

Updated at: 27-04-2024

Show more information

Project acronym TKI resistance

Secreted PD-L1 variants mediate resistance to PD-L1 blockade therapy in non–small cell lung cancer

Project: TKI resistance

Updated at: 27-04-2024

Show more information

Project acronym TKI resistance

Circulating Tumor DNA Analysis for Patients with Oncogene-Addicted NSCLC With Isolated Central Nervous System Progressio...

Project: TKI resistance

Updated at: 27-04-2024

Show more information

Project acronym TKI resistance

Oncogenic Fusions May Be Frequently Present at Resistance of EGFR Tyrosine Kinase Inhibitors in Patients With NSCLC: A...

Project: TKI resistance

Updated at: 27-04-2024

Show more information

Project acronym TKI resistance

Molecular mechanisms of resistance to BRAF and MEK inhibitors in BRAFV600E non–small cell lung cancer

Project: TKI resistance

Updated at: 27-04-2024

Show more information

Project acronym TKI resistance

Oncogene addiction in non-small cell lung cancer: Focus on ROS1 inhibition

Project: TKI resistance

Updated at: 27-04-2024

Show more information

Project acronym TKI resistance

Clinicogenomic analysis of FGFR2-rearranged cholangiocarcinoma identifies correlates of response and mechanisms of resis...

Project: TKI resistance

Updated at: 27-04-2024

Show more information

Project acronym TKI resistance

Feasibility and first reports of the MATCH-R repeated biopsy trial at Gustave Roussy

Project: TKI resistance

Updated at: 27-04-2024

Show more information

Project acronym TKI resistance

Cholangiocarcinoma with STRN-ALK translocation treated with ALK inhibitors

Project: TKI resistance

Updated at: 27-04-2024

Show more information

Project acronym TKI resistance

Resistance Mechanisms to ALK Tyrosine Kinase Inhibitors (TKIs) in NSCLC

Project: TKI resistance

Updated at: 27-04-2024

Show more information

Project acronym TKI resistance

Resources

Selected filters:

Circulating Tumor DNA Genomics Reveal Potential Mechanisms of Resistance to BRAF-Targeted Therapies in Patients with BRA...

Clinical Relevance of an Amplicon-Based Liquid Biopsy for Detecting ALK and ROS1 Fusion and Resistance Mutations in Pati...

Acquired Resistance Mutations to ALK Inhibitors Identified by Single Circulating Tumor Cell Sequencing in ALK -Rearrange...

Diverse resistance mechanisms to the third-generation ALK inhibitor lorlatinib in ALK-rearranged lung cancer

<p>Profile of entrectinib and its potential in the treatment of ROS1-positive NSCLC: evidence to date</p>

Facts and new hopes on selective FGFR inhibitors in solid tumors

Gilteritinib overcomes lorlatinib resistance in ALK-rearranged cancer

Making the first move in EGFR-driven or ALK-driven NSCLC: first-generation or next-generation TKI?

Periodic Reporting for period 4 - TKI resistance (Resistance mechanisms to tyrosine kinase inhibitors in solid tumors)

Sequential ALK Inhibitors Can Select for Lorlatinib-Resistant Compound ALK Mutations in ALK-Positive Lung Cancer

Single cell DNA-seq depicts clonal evolution of multiple driver alterations in osimertinib resistant patients

Lorlatinib in ALK- and ROS1-positive NSCLC: the future has a start

Secreted PD-L1 variants mediate resistance to PD-L1 blockade therapy in non–small cell lung cancer

Circulating Tumor DNA Analysis for Patients with Oncogene-Addicted NSCLC With Isolated Central Nervous System Progressio...

Oncogenic Fusions May Be Frequently Present at Resistance of EGFR Tyrosine Kinase Inhibitors in Patients With NSCLC: A...

Molecular mechanisms of resistance to BRAF and MEK inhibitors in BRAFV600E non–small cell lung cancer

Oncogene addiction in non-small cell lung cancer: Focus on ROS1 inhibition

Clinicogenomic analysis of FGFR2-rearranged cholangiocarcinoma identifies correlates of response and mechanisms of resis...

Feasibility and first reports of the MATCH-R repeated biopsy trial at Gustave Roussy

Cholangiocarcinoma with STRN-ALK translocation treated with ALK inhibitors

Resistance Mechanisms to ALK Tyrosine Kinase Inhibitors (TKIs) in NSCLC